The US Environmental Protection Agency (EPA) has made significant strides in assessing the health risks associated with formaldehyde, culminating in the recent...
A recent study has highlighted the occupational hazards associated with formaldehyde exposure, significantly impacting not only pathologists and laboratory tec...
We are pleased to have participated in the 36th European Congress of Pathology (ECP 2024), the largest event in the pathology field in Europe, held from Septemb...
Starting July 12, 2024 the healthcare sector must comply with the new, stricter occupational exposure limits for formaldehyde, marking the end of the 5-year tra...
Addax Biosciences is excited to share that our acid-free glyoxal formulation has been used in a recent study, demonstrating superior performance in preserving n...
We are pleased to share another significant step in the entrepreneurial development of Addax Biosciences: Fintech Partners, investment sub-holding controlled by...
We are excited to share another remakable recent study on alternative protocols of tissue fixation that have the potential to revolutionize the interpretation o...
An open label, non-inferiority, multicentric trial proves that Glyoxal Acid-Free (GAF®) histological fixative is a suitable alternative to Formalin. The tri...
We are pleased to share the remarkable outcomes of a recent multi-institutional groundbreaking study: NON-TOXIC ACID-FREE GLYOXAL FIXATIVE FOR VETERINARY HIS...
We are pleased to announce that our GAF® formalin free fixative solution joined the World’s greenest hospital initiative. The fictional city of Grønnköping...